Neuroprotective Agents

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
DrugDrug NameDrug Indication
DB00273TopiramateTopiramate is indicated for the following conditions: - Monotherapy for partial onset or primary generalized tonic-clonic seizures in patients over 2 years of age. - Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for adult and pediatric patients. - Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients over 2 years of age. - Prophylaxis of migraine headache in adults.[FDA label] A seizure is an abnormal, unregulated electrical discharge occurring in the brain's cortical gray matter. This electrical response produces a transient interruption in the normal brain function which in order produces altered awareness, abnormal sensations, focal involuntary movements or convulsions. The type of seizure can be classified according to the type of onset followed by a type of seizure.[L5548] A migraine headache is a [ulsating or throbbing pain that can be presented in one of both sides of the head and it can be worsened by external stimuli such as physical activity, light, sounds, and odors.[L5551] Topiramate has been commonly investigated and used off-label for weight reduction in patients with obesity or diabetes.[A175240]
DB00740RiluzoleFor the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
DB00959MethylprednisoloneAdjunctive therapy for short-term administration in rheumatoid arthritis.
DB00989RivastigmineFor the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
DB01037SelegilineMonotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.
DB01166CilostazolIndicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
DB01367RasagilineFor the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
DB01520TenocyclidineBecause of its high affinity for the phencyclidine binding site on the NMDA receptor, the 3H radiolabelled form of tenocyclidine is widely used in research into NMDA receptors.
DB022077-NitroindazoleNot Available
DB02855N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineNot Available
DB04864Huperzine AInvestigated for use/treatment in alzheimer's disease.
DB05010SGS-742Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), memory loss, and schizophrenia and schizoaffective disorders.
DB05660D-JNKI-1Investigated for use/treatment in hearing loss.
DB06230NalmefeneIndicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification [L1024]. Indicated for the complete or partial reversal of opioid drug effects, including respiratory depression - induced by either natural or synthetic opioids - or in the management of known or suspected opioid overdose [FDA Label].
DB06283ZiconotideNot Available
DB06444DexanabinolInvestigated for use/treatment in traumatic brain injuries and neurologic disorders.
DB06458RemacemideInvestigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease.
DB06470ClomethiazoleInvestigated for use/treatment in strokes.
DB06479PropentofyllineInvestigated for use/treatment in alzheimer's disease.
DB07744Z-Val-Ala-Asp fluoromethyl ketoneNot Available
DB09210PiracetamIndicated in adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies [L1125].
DB12116Epigallocatechin gallateNot Available
DB12131VinpocetineNot Available
DB12449TempolNot Available
DB12749ButylphthalideNot Available
DB12869EliprodilNot Available
DB13050TirilazadNot Available
DB13082NefiracetamNot Available
DB13096GacyclidineNot Available
DB13546NizofenoneNot Available
DB13758MeclofenoxateNot Available
DB13806LinopirdineNot Available
DB13863FosfructoseNot Available
DB14644Methylprednisolone hemisuccinateNot Available
DB14682DextrorphanNot Available
DB12610EbselenNot Available
DB01430AlmitrineFor the treatment of chronic obstructive pulmonary disease.
DB15231BrimapitideNot Available
DB12243EdaravoneIndicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of ALS.
DrugDrug NameTargetType
DB00273TopiramateGamma-aminobutyric acid receptor subunit alpha-1target
DB00273TopiramateSodium channel protein type 1 subunit alphatarget
DB00273TopiramateCarbonic anhydrase 2target
DB00273TopiramateCarbonic anhydrase 4target
DB00273TopiramateGlutamate receptor ionotropic, kainate 1target
DB00273TopiramateCytochrome P450 2C19enzyme
DB00273TopiramateCytochrome P450 3A4enzyme
DB00273TopiramateGABA-A receptor (anion channel)target
DB00273TopiramateCarbonic anhydrase 1target
DB00273TopiramateCarbonic anhydrase 3target
DB00273TopiramateGlutamate receptor 1target
DB00740RiluzoleSodium channel protein type 5 subunit alphatarget
DB00740RiluzoleCytochrome P450 1A2enzyme
DB00740RiluzoleCystine/glutamate transportertarget
DB00740RiluzoleATP-binding cassette sub-family G member 2transporter
DB00740RiluzoleCytochrome P450 1A1enzyme
DB00959MethylprednisoloneGlucocorticoid receptortarget
DB00959MethylprednisoloneCytochrome P450 3A4enzyme
DB00959MethylprednisoloneMultidrug resistance protein 1transporter
DB00989RivastigmineAcetylcholinesterasetarget
DB00989RivastigmineCholinesterasetarget
DB00989RivastigmineCytochrome P450 3A4enzyme
DB01037SelegilineAmine oxidase [flavin-containing] Btarget
DB01037SelegilineCytochrome P450 2B6enzyme
DB01037SelegilineAmine oxidase [flavin-containing] Atarget
DB01037SelegilineCytochrome P450 2A6enzyme
DB01037SelegilineCytochrome P450 3A4enzyme
DB01037SelegilineMultidrug resistance protein 1transporter
DB01037SelegilineCytochrome P450 1A2enzyme
DB01037SelegilineCytochrome P450 2C19enzyme
DB01037SelegilineCytochrome P450 2C8enzyme
DB01037SelegilineCytochrome P450 2C9enzyme
DB01037SelegilineCytochrome P450 2D6enzyme
DB01037SelegilineCytochrome P450 2E1enzyme
DB01166CilostazolcGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB01166CilostazolCytochrome P450 2C19enzyme
DB01166CilostazolCytochrome P450 3A4enzyme
DB01166CilostazolCytochrome P450 3A5enzyme
DB01166CilostazolCytochrome P450 3A7enzyme
DB01166CilostazolCytochrome P450 1A2enzyme
DB01166CilostazolCytochrome P450 2D6enzyme
DB01367RasagilineApoptosis regulator Bcl-2target
DB01367RasagilineAmine oxidase [flavin-containing] Btarget
DB01367RasagilineCytochrome P450 1A2enzyme
DB01520TenocyclidineGlutamate receptor ionotropic, NMDA 3Atarget
DB01520TenocyclidineGlutamate receptor ionotropic, NMDA 3Btarget
DB01520TenocyclidineGlutamate receptor ionotropic, NMDA 2Atarget
DB01520TenocyclidineGlutamate receptor ionotropic, NMDA 2Ctarget
DB01520TenocyclidineGlutamate receptor ionotropic, NMDA 2Btarget
DB01520TenocyclidineGlutamate receptor ionotropic, NMDA 2Dtarget
DB01520TenocyclidineAlpha-7 nicotinic cholinergic receptor subunittarget
DB022077-NitroindazoleNitric oxide synthase, endothelialtarget
DB022077-NitroindazoleNitric oxide synthase, inducibletarget
DB02855N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineCathepsin Btarget
DB04864Huperzine AAcetylcholinesterasetarget
DB05010SGS-742Gamma-aminobutyric acid type B receptor subunit 1target
DB05010SGS-742Gamma-aminobutyric acid type B receptor subunit 2target
DB06230NalmefeneMu-type opioid receptortarget
DB06230NalmefeneKappa-type opioid receptortarget
DB06230NalmefeneDelta-type opioid receptortarget
DB06230NalmefeneUDP-glucuronosyltransferase 2B7enzyme
DB06230NalmefeneUDP-glucuronosyltransferase 1-3enzyme
DB06230NalmefeneUDP-glucuronosyltransferase 1-8enzyme
DB06283ZiconotideCytochrome P450 3A4enzyme
DB06444DexanabinolTumor necrosis factortarget
DB06458RemacemideCytochrome P450 3A4enzyme
DB06470ClomethiazoleGamma-aminobutyric acid receptor subunit alpha-1target
DB06470ClomethiazoleCytochrome P450 2A6enzyme
DB06470ClomethiazoleCytochrome P450 2B6enzyme
DB06470ClomethiazoleCytochrome P450 2C19enzyme
DB06470ClomethiazoleCytochrome P450 3A4enzyme
DB06479PropentofyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB06479PropentofyllineCytochrome P450 1A2enzyme
DB07744Z-Val-Ala-Asp fluoromethyl ketoneCaspase-1target
DB12116Epigallocatechin gallateAryl hydrocarbon receptortarget
DB12116Epigallocatechin gallateDNA (cytosine-5)-methyltransferase 1target
DB12116Epigallocatechin gallateDihydrofolate reductase, mitochondrialtarget
DB12131VinpocetineCytochrome P450 3A4enzyme
DB12610EbselenBifunctional epoxide hydrolase 2target
DB01430AlmitrineSodium/potassium-transporting ATPase subunit alpha-1target
DB12243EdaravoneSolute carrier family 22 member 6transporter
DB12243EdaravoneSolute carrier family 22 member 8transporter